Nabi completes enrollment in NicVAX study; Crucell reports Q3 net loss;

Vaccine Research

Nabi Biopharmaceuticals has completed enrollment in the second Phase III clinical trial of NicVAX, the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse. Nabi release

Shares of Bavarian Nordic jumped seven percent after the Danish drug developer asserted that it is close to landing a big pharma partner for its closely watched prostate cancer vaccine, which is slated to begin a late-stage trial next year. News

Eden Biodesign has announced the execution of a non-exclusive vendor network agreement with Crucell. Eden as a result has become a pre-approved authorized provider of process development and cGMP manufacturing services using Crucell's proprietary PER.C6 cell line technology. Under the terms of the agreement Eden Biodesign will be able to offer its services to Crucell's PER.C6 licensees in the field of vaccines and gene therapy. Eden release

Vaccine Market

Crucell N.V. on Tuesday swung to a third-quarter net loss after writing down its contaminated pediatric Quinvaxem vaccine inventory and said it now expects full-year revenues will be in line with 2009. Crucell release | News

If you're dreading your next flu shot, here's good news: Needle-free injection technology could be coming to a health clinic near you. "I can't say it's entirely painless, because that's subjective," says Kathleen Callendar, 69, the founder of PharmaJet, a startup company based in Golden, CO. "But it gives a more gentle injection--kind of like a tiny rubber band snapping against you." Article

Rockville-based vaccine maker Novavax posted a third quarter net loss of $10.4 million, or 10 cents per share, citing higher research and development spending for its flu vaccine candidates. Story

The HPV vaccine was approved in 2006 as the first vaccine that can prevent a type of cancer. The vaccine protects against several common strains of human papilloma virus, which causes genital warts and can lead to cervical cancer. However, a new study show that a majority of young women who are eligible for the vaccine are either not getting it or are not following the three-shot protocol to be fully immunized. Article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.